About Us

Genis is an innovative Icelandic biotechnology company, pioneering the development of therapeutic chitin derivatives.

Our goal is to address an unmet need by providing effective therapeutic solutions across a number of inflammatory diseases, including lung diseases such as asthma and COPD, type II diabetes, rheumatoid arthritis and endometriosis.

We are also developing a number of orthobiologic applications that are based on the regenerative tissue and osteogenic activities and anti-bacterial properties of chitin derivatives.

Therapeutic program

Our drug development program is a result of extensive research on short chain chitin derivatives and its therapeutic potential over a number of years.

We have developed proprietary short chain chitosan molecules that target members of the chitinase-like protein (CLP) family. Mammalian chitinases and the CLPs have been shown to be involved in inflammation and formation of scar tissue. By targeting the CLPs, we have developed a therapeutic strategy that combats inflammation and stimulates natural tissue regeneration.

Our Mission

Genis is committed to deliver products that will improve the quality of life of humans. Our aim is to bring a suite of products to market based on solid scientific foundation that seeks to utilize regenerative mechanisms developed by nature. Our pride lies in the development of health products that are recommended by patients and preferred by doctors, to bring medical benefits to society and long-term returns to our investors. We don’t intend to retreat quietly into old age, and we don’t expect our customers to either.